looks set11 May 2016 10:59
better year and about to turn IMHO - COULD BE AT BOTTOM AT PRESENT
Outlook
The Company spent much of 2015 concentrating on the re-application for Chinese GMP certification. As previously announced, this has been achieved. This, combined with the renewal of the Company's Drug Production Permit means that there are no regulatory barriers to the expansion of the Company's TCM (including Bian Tong Pian) and Homoharringtonine sales.
The Company intends to spend much of 2016 in leveraging the re-certification, paying particular attention to recovering market share in Homoharringtonine and in expanding its distribution of Bain Tong Pian. The sales of both of these products have been severely constrained by the unstable GMP environment which has now come to an end.